Screener
Ultragenyx Pharmaceutical RARE Accounts Receivable
Accounts Receivable at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's accounts receivable?
- Ultragenyx Pharmaceutical (RARE) reported accounts receivable of $200M in Q2 2026.
- How has Ultragenyx Pharmaceutical's accounts receivable changed year-over-year?
- Ultragenyx Pharmaceutical's accounts receivable increased by 60.7% year-over-year, from $124.46M to $200M.
- What is the long-term trend for Ultragenyx Pharmaceutical's accounts receivable?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's accounts receivable has grown at a 46.9% compound annual growth rate (CAGR), from $23.09M to $158M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Ultragenyx Pharmaceutical's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude